Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Non-Current Assets (2016 - 2025)

Nutex Health's Non-Current Assets history spans 16 years, with the latest figure at $360.4 million for Q1 2025.

  • For Q1 2025, Non-Current Assets rose 18.58% year-over-year to $360.4 million; the TTM value through Mar 2025 reached $1.4 billion, changed 0.39%, while the annual FY2024 figure was $362.8 million, 18.04% up from the prior year.
  • Non-Current Assets for Q1 2025 was $360.4 million at Nutex Health, down from $362.8 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $712.5 million in Q2 2022 and bottomed at $4279.0 in Q4 2021.
  • The 5-year median for Non-Current Assets is $318.7 million (2024), against an average of $281.0 million.
  • The largest annual shift saw Non-Current Assets crashed 66.57% in 2021 before it soared 7800275.34% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $4279.0 in 2021, then skyrocketed by 7800275.34% to $333.8 million in 2022, then dropped by 7.9% to $307.4 million in 2023, then rose by 18.04% to $362.8 million in 2024, then dropped by 0.67% to $360.4 million in 2025.
  • Per Business Quant, the three most recent readings for NUTX's Non-Current Assets are $360.4 million (Q1 2025), $362.8 million (Q4 2024), and $318.7 million (Q3 2024).